The cost-effectiveness of sacubitril/valsartan (LCZ696) in the treatment of patients with heart failure with reduced ejection fraction in Norway

28 August 2016 (08:57 - 09:06)
Organised by:
Add to my library
Congress Presentation Part of: Pharmacologic approaches in HF: could we do better? Heart failure, other ESC Premium Access ESC Congress 2016